Clinical and molecular characteristics, therapeutic strategies, and prognosis of non-small cell lung cancer patients harboring primary and acquired BRAF mutations
Together, our study demonstrates that primary and acquired <i>BRAF</i>-mutant patients show distinct differences in some clinical and molecular characteristics, but acquired <i>BRAF</i>/<i>EGFR</i> co-mutated and primary <i>BRAF</i>/<i>EGFR</i> non-19del co-mutated patients may both respond to triple-targeted therapy.
Authors
- Jingya Zhao (ORCID: https://orcid.org/0000-0002-7387-1216)
- Mengchen Lyu
- Zhiyao Bao
- Beili Gao
- Ziwei Xu (ORCID: https://orcid.org/0000-0002-6143-182X)
- Yi Xiang (ORCID: https://orcid.org/0000-0002-0724-6359)
- Xianwen Sun (ORCID: https://orcid.org/0009-0009-9204-920X)
- Ling Hui Zhou (ORCID: https://orcid.org/0000-0001-9868-2561)
- Xiaohong Chen (ORCID: https://orcid.org/0000-0002-9797-8384)
- Jun Zhou (ORCID: https://orcid.org/0009-0000-2512-9036)
- Lei Dong (ORCID: https://orcid.org/0000-0003-2623-3198)
- Yue Hu (ORCID: https://orcid.org/0009-0004-4409-1503)
- Ran Zeng
- Xiangran Feng
Institutions
- Shanghai Jiao Tong University (CN)
- Ruijin Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-04-02
- DOI
- https://doi.org/10.3389/fonc.2025.1514653
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Ruijin Hospital